Thursday, September 3, 2020 Daily Archives

A Smart Path for Novel Biologics

by

Roche Pharma Research and Early Development (pRED) was faced with a challenge: double the number of projects in process development without significantly increasing headcount. Pawel Linke, a pRED lab automation specialist, tells the story of how the group approached this challenge with a focus on obtaining high quality data through automation and by integrating independent lab systems and devices to streamline their workflow. Implementation of high-throughput process development systems requires an orchestrated approach of both hardware and software solutions, so…

September 3, 2020

Embedding Your Drug Strategy Within a Solid Foundation for Success

by

Demand for drugs and therapeutics is growing thanks to the globalization of pharmaceutical-based medicine. Manufacturing new drugs and getting them to market faster, more economically and safely demands development strategies and business models that support successful outcomes for both investors and patients. Outsourcing has become an increasingly attractive business model for pharma as companies seek partners who can deliver comprehensive end-to-end drug substance and drug product development. It has prompted contract manufacturing organizations (CMOs) to consolidate and expand to create…

September 3, 2020

Proteinea using fly larvae as ‘mini-bioreactors’ in challenge to industry

by

Producing recombinant proteins in fly larvae instead of single-cell technologies could reduce biomanufacturing costs by up to 90%, says bioprocess startup firm Proteinea. Proteinea, a US and Egyptian startup, is looking to change the economics of biomanufacturing. The firm challenging the standard of using stainless-steel or single-use bioreactor systems to produce biologics by instead leveraging its insect-based biotechnology platform. Rather than produce a recombinant protein in single bacteria, yeast or mammalian cells, the firm uses InsectaPro, its platform comprising of…

September 3, 2020

Catalent cites biologics as growth driver and forecasts COVID gains in 2021

by

Catalent says investments in biologics – particularly in the cell and gene therapy space – drove Q4 gains and positioned it as the “go to†COVID CDMO. Catalent’s revenue for the three months ending June was $947.6 million, up 31% on the comparable quarter last year. The contract development and manufacturing organization (CDMO) made a number of purchases in the cell and gene therapy space in recent years. In February, it bought Masthercell from Orgenesis and in 2019 it acquired…

September 3, 2020